
Bantam Pharmaceutical: Cost-efficient oncology drug discovery and development with experienced leadership.
Bantam Pharmaceutical, founded with a mission to redefine cancer care, focuses on cost-efficient oncology drug discovery and development. The company leverages deep expertise in R&D and strategic partnerships to advance its pipeline, including its lead candidate BTM-3566. Bantam aims to address unmet needs in oncology by channeling the power of mitochondrial dynamics, offering innovative solutions for cancer treatment.
Bantam's management team and scientific advisory board include prominent academic and industry leaders with extensive experience in drug development and executive roles. Notable achievements include the advancement of BTM-3566 through critical development stages. The company’s impact lies in its potential to bring groundbreaking oncology treatments to market, improving patient outcomes and setting new standards in cancer care.

Bakx Therapeutics
bakxtx.com

NantBio

OncoTartis

Camino Pharma
caminopharma.com

MBC Pharma
mbcpharma.com

Novita Pharmaceuticals
novita-pharm.com

Bionpharma
bionpharma.com

NiKang Therapeutics

Ernest Pharmaceuticals
ernestpharma.com

BioNumerik Pharmaceuticals

Tigris Pharmaceuticals
tigrispharma.com

Ensem Therapeutics
ensemtx.com

OnCusp Therapeutics
oncusptx.com
Altiris Therapeutics

BioMimetix Pharmaceutical
Companies similar to Bantam Pharmaceutical include Bakx Therapeutics, NantBio, OncoTartis and Camino Pharma.
Bantam Pharmaceutical was founded in 2015.
Bantam Pharmaceutical's headquarters is located in New York City, NY, US.
Bantam Pharmaceutical's most recent funding round was for $25M (USD) in September 2021.
As of Sep 16, 2021, Bantam Pharmaceutical has raised a total of $25M (USD).
Bantam Pharmaceutical has 7 employees as of Feb 5, 2024.